Crossmark Global Holdings Inc. Has $433,000 Stock Position in Masimo Co. (NASDAQ:MASI)

Crossmark Global Holdings Inc. raised its holdings in shares of Masimo Co. (NASDAQ:MASI) by 14.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,248 shares of the medical equipment provider’s stock after acquiring an additional 409 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Masimo were worth $433,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in MASI. Thrivent Financial for Lutherans boosted its holdings in shares of Masimo by 42.1% during the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after purchasing an additional 360,497 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Masimo by 107.8% in the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after acquiring an additional 351,523 shares during the last quarter. Bamco Inc. NY purchased a new stake in shares of Masimo during the first quarter worth $50,781,000. Farallon Capital Management LLC raised its holdings in shares of Masimo by 13.6% during the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after acquiring an additional 177,914 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Masimo by 45.9% during the second quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock valued at $66,201,000 after purchasing an additional 165,257 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on MASI. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Wells Fargo & Company raised their price objective on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. BTIG Research boosted their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Piper Sandler raised their price target on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.67.

Masimo Trading Up 0.6 %

NASDAQ:MASI opened at $161.07 on Friday. The company’s 50 day moving average is $138.18 and its 200-day moving average is $126.95. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12 month low of $91.25 and a 12 month high of $173.90. The firm has a market cap of $8.62 billion, a price-to-earnings ratio of 111.08 and a beta of 0.97.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. Equities analysts anticipate that Masimo Co. will post 4.04 EPS for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.